tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Can-Fite BioPharma announces new findings for Namodenoson
PremiumThe FlyCan-Fite BioPharma announces new findings for Namodenoson
2M ago
Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year
Premium
The Fly
Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year
3M ago
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
Premium
The Fly
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
4M ago
Can-Fite BioPharma to present Phase IIa pancreatic cancer study progress
PremiumThe FlyCan-Fite BioPharma to present Phase IIa pancreatic cancer study progress
6M ago
Can-Fite raises $175M to date for namodenoson, piclidenoson development
Premium
The Fly
Can-Fite raises $175M to date for namodenoson, piclidenoson development
7M ago
Can-Fite BioPharma says medical centers seek authorization for namodenoson
Premium
The Fly
Can-Fite BioPharma says medical centers seek authorization for namodenoson
8M ago
Can-Fite BioPharma trading halted, news pending
PremiumThe FlyCan-Fite BioPharma trading halted, news pending
8M ago
Can-Fite BioPharma announces completion of analysis of current partnerships
Premium
The Fly
Can-Fite BioPharma announces completion of analysis of current partnerships
8M ago
Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year
Premium
The Fly
Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100